Vitaliy Katsenelson • April 18, 2017
How to stay prudent when the market is partying like it’s (precrash) 1999.
Michael Kimelman • April 17, 2017
Michael Kimelman was convicted of insider trading, inextricably tied to the infamous Raj Rajaratnam. He went to jail. Now he tells his story.
Joe McGrath • April 12, 2017
The Chicago-based company said it will shutter CME Europe and CME Clearing Europe by the end of the year.
Joe McGrath • April 10, 2017
A fintech campus in the City of London is set to rival Canary Wharf’s Level 39.
Jeffrey Kutler • April 10, 2017
After WikiLeaks published techniques used by the CIA for breaking into smartphones, the biggest leak in the spy agency’s history faded away.
Joe McGrath • April 05, 2017
The electric carmaker’s soaring market value has sparked debate over ‘ethical’ holdings in environmental, social and governance strategies.
Joe McGrath • April 03, 2017
Pressure to cut costs by replacing humans with robots may end up hurting firms if they’re not careful, PwC says.
Staff • March 29, 2017
Stock exchanges and other market infrastructure firms are carving out a larger share of revenue in financial services, McKinsey says.
Joe McGrath • March 28, 2017
The U.K. fund manager says the odds of leaving the trading bloc without a trade deal are “sufficiently high to worry.”
Staff • March 27, 2017
The bronze sculpture promoting SSGA’s gender balance campaign was granted an extended permit by New York City Mayor Bill de Blasio.
Jeffrey Kutler • March 27, 2017
The SEC and deputy director of its economic and risk analysis division stand out as regulatory technology innovators.
The Editors • March 22, 2017
David Rubenstein's Carlyle Group raised immense amounts of capital on the back of its famous board members. Then, the co-founder recounts, it made a lot of money for its investors.
Joe McGrath • March 21, 2017
Concerns are mounting that portfolios may lack resilience against global event risks.
Julie Segal • March 20, 2017
State Street Global Advisors used a savvy social media campaign to call attention to its “Fearless Girl” campaign — and its SHE ETF product.
Vitaliy Katsenelson • March 08, 2017
In my previous column I explained why we are partial to pharmaceuticals, a sector politicians love to hate. Here’s how we’re playing our view.
© 2017 Institutional Investor LLC. All material subject to strictly enforced copyright laws.
Please read our
Term and Conditions and